CrackitToday App

iNCOVACC : World’s First Intranasal Vaccine Gets Approval

Kumari Sonali

iNCOVACC : World’s First Intranasal Vaccine Gets Approval

World’s first Intranasal Vaccine iNCOVACC has recently received approval for Covid booster doses from Drugs Controller General of India (DCGI).

  • It is developed by Bharat Biotech International Limited.
  • It was developed in partnership with Washington University, St Louis, which had designed and developed the recombinant adenoviral vectored construct and evaluated in pre-clinical studies for efficacy.
  • The approval is under Restricted Use in Emergency Situation for ages 18 and above in India, for heterologous booster doses.
  • iNCOVACC is a recombinant replication deficient adenovirus vectored vaccine with a pre-fusion stabilised SARS-CoV-2 spike protein.
  • It is the world’s first intranasal vaccine to receive both primary series and heterologous booster approval.
  • The vaccine candidate was evaluated in Phases I, II and III clinical trials with successful results and has been specifically formulated to allow intranasal delivery through nasal drops.
  • It is stable at 2-8 degrees Celsius for easy storage and distribution.

...Read more on our test console

...Read these too

  • Bharat Biotech’s BBV154 : Intranasal Covid-19 Vaccine

    Bharat Biotech’s BBV154: Bharat Biotech’s BBV154 is the first publicized attempt at getting an intranasal Covid-19 vaccine. Intranasal vaccines are most commonly administered as injectable shots into the muscles (intramuscular)…

  • Vaccine Hesitancy

    Vaccine Hesitancy:   While last year, before the second wave, vaccine hesitancy was ascribed to the low uptake, it is quite likely now that people are exercising their option of…

  • Chikungunya Vaccine

    Chikungunya Vaccine: International Vaccine Institute (IVI) has announced that Bharat Biotech’s Chikungunya vaccine candidate (BBV87) has entered into Phase II and III clinical trials. Currently, there is no commercial chikungunya…